Oncology Focus Areas:
Our other therapy areas

    • {%itemName%}
        {%brandMenuItems%}
    • {%itemName%} {%arrowSpan%}
        {%subBrandMenuItems%}
    • {%itemName%} {%arrowSpan%}
        {%productMenuItems%}
    • {%itemKeyName%} {%itemBadges%} {%arrowSpan%}
      {%selfProduct%}
    • {%itemName%}
      • {%countries%}
    • {%allMenuItem%}
      • {%languages%}

      • This website is for UK Healthcare Professionals only

      UK-VNCAML-220206. Date of Preparation: November 2022.

      FRONTIERS promotional meetings are fully funded and organised by AbbVie for UK healthcare professionals.

      On demand: Access content from previous meetings

      15th December 2022

      Frontiers webinar was a one hour CPD accredited live webinar focusing on AML management with venetoclax. Please access the recorded footage below.

      Dr Chun Yew Fong 

      AML management with venetoclax: current practice & patient experience

      9th – 10th September 2022

      FRONTIERS was a two-day, CPD accredited, in-person meeting in London. The meeting brought together a UK and international faculty of AML and CLL thought leaders to review emerging data, explore practical management and learn about approaches to service design.

      We invite you to view key presentations from the FRONTIERS meeting. 

      Dr Caroline Alvarez

      Practical management of AML patients with venetoclax

      Dr Paul Cahalin

      Setting up an ambulatory chemotherapy service – the Lancashire experience

      Thomas LeBlanc 

      AML management: reflections on current practice, patient experience and treatment decision-making              

      Venclyxto in combination with a hypomethylating agent is indicated for the treatment of adult patients with newly diagnosed acute myeloid leukaemia (AML) who are ineligible for intensive chemotherapy1

      References

      1. VENCLYXTO Summary of Product Characteristics.
      VENCLYXTO AML PRESCRIBING INFORMATION

       

      Adverse events should be reported. Reporting forms and information can be found at yellowcard.mhra.gov.uk.

      Adverse events should also be reported to AbbVie on [email protected]

      UK-VNCAML-230088. Date of Preparation: August 2023.

      Adverse events should be reported. Reporting forms and information can be found at https://yellowcard.mhra.gov.uk or via the MHRA Yellow Card app, available in the Google Play or Apple App Stores. Adverse events should also be reported to AbbVie on [email protected]

       

      This website is for UK Healthcare Professionals only

      UK-ABBV-230225. Date of preparation June 2023. This website has been developed and funded by AbbVie Ltd.

      © 2023 AbbVie Ltd. All rights reserved. Registered Number: 08004972 England.